Propanc Biopharma Faces Nasdaq Delisting Over Minimum Bid Price Violation
Bitget2026/10/29 21:25- Propanc Biopharma received Nasdaq’s delisting notice on October 23, 2026; its securities face delisting November 2, 2026, unless it requests an appeal.
- Closing bids for its common stock failed Nasdaq’s $1 minimum requirement for 30 consecutive business days before October 21, 2026.
- A reverse stock split within the prior year makes it ineligible for the usual 180-calendar-day compliance period.
- Management intends to appeal by October 30, 2026; requesting an appeal would stay delisting pending a hearings panel decision.
- The company believes it cured the bid-price deficiency following the notice; delisting could reduce stock liquidity and constrain equity financing.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Morgan Stanley: AI capital expenditure may reach 10 to 15 trillions USD in the next 10 years
Morgan Stanley stated that capital expenditure in the artificial intelligence (AI) sector could reach $10-15 trillions over the next decade.
Morgan Stanley: Apple's target price lowered to $350
Autoliv completes acquisition of MCF Safety Belts
Refining profits surge and oil prices soar; Saudi Aramco Q3 profits grow by 9% and maintains a dividend of 21.9 billions USD.
Driven by rising refining profits and oil prices, Saudi Aramco's third-quarter profits increased by 9%.
Crypto prices
More
